Mar 14, 2023 / 02:45PM GMT
Luke England Sergott - Barclays Bank PLC, Research Division - Research Analyst
Everybody. Luke Sergott here at Barclays to cover Life Sciences Tools and Diagnostics. With me, I have Paul Surdez, VP, Investor Relations; and Tom Castellano, CFO of Catalent. So we're already 45 seconds behind schedule, so I guess we could jump right into the questions here.
Questions and Answers:
Luke England Sergott - Barclays Bank PLC, Research Division - Research AnalystYou made a comment on the last quarter, where you were talking about revisiting your rev rec policy and how that's going to impact the rest of the business. Talk about really the genesis of that comment, and how the business has changed and why you would need to reconsider?
Thomas P. Castellano - Catalent, Inc. - Senior VP & CFO
Yes, sure. So thanks, everyone, for having me, Luke, here, and I appreciate the question.
So the question around revenue recognition was really tied specifically to the relationship that Catalent has with Sarepta and their
Trustpilot
